PRVCF Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to PreveCeutical Medical, Inc.'s net margin of 42.95%. PreveCeutical Medical, Inc.'s return on equity of -- beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

PreveCeutical Medical, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 2.56%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than PreveCeutical Medical, Inc., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than PreveCeutical Medical, Inc..

PreveCeutical Medical, Inc. has a beta of 0.617, which suggesting that the stock is 38.252% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

PreveCeutical Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PreveCeutical Medical, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

PreveCeutical Medical, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. PreveCeutical Medical, Inc.'s net income of -$623K is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, PreveCeutical Medical, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PreveCeutical Medical, Inc. is -- versus 8.63x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Instadose Pharma Corp. has a net margin of -- compared to PreveCeutical Medical, Inc.'s net margin of --. PreveCeutical Medical, Inc.'s return on equity of -- beat Instadose Pharma Corp.'s return on equity of --.

PreveCeutical Medical, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Instadose Pharma Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that PreveCeutical Medical, Inc. has higher upside potential than Instadose Pharma Corp., analysts believe PreveCeutical Medical, Inc. is more attractive than Instadose Pharma Corp..

PreveCeutical Medical, Inc. has a beta of 0.617, which suggesting that the stock is 38.252% less volatile than S&P 500. In comparison Instadose Pharma Corp. has a beta of -714.392, suggesting its less volatile than the S&P 500 by 71539.203%.

PreveCeutical Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instadose Pharma Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PreveCeutical Medical, Inc. pays -- of its earnings as a dividend. Instadose Pharma Corp. pays out -- of its earnings as a dividend.

PreveCeutical Medical, Inc. quarterly revenues are --, which are larger than Instadose Pharma Corp. quarterly revenues of --. PreveCeutical Medical, Inc.'s net income of -$623K is higher than Instadose Pharma Corp.'s net income of --. Notably, PreveCeutical Medical, Inc.'s price-to-earnings ratio is -- while Instadose Pharma Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PreveCeutical Medical, Inc. is -- versus -- for Instadose Pharma Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -- compared to PreveCeutical Medical, Inc.'s net margin of --. PreveCeutical Medical, Inc.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

PreveCeutical Medical, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 483.09%. Given that Oncolytics Biotech, Inc. has higher upside potential than PreveCeutical Medical, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than PreveCeutical Medical, Inc..

PreveCeutical Medical, Inc. has a beta of 0.617, which suggesting that the stock is 38.252% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

PreveCeutical Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PreveCeutical Medical, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

PreveCeutical Medical, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. PreveCeutical Medical, Inc.'s net income of -$623K is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, PreveCeutical Medical, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PreveCeutical Medical, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Venus Concept, Inc. has a net margin of -- compared to PreveCeutical Medical, Inc.'s net margin of -163.68%. PreveCeutical Medical, Inc.'s return on equity of -- beat Venus Concept, Inc.'s return on equity of -1236.95%.

PreveCeutical Medical, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 6601.15%. Given that Venus Concept, Inc. has higher upside potential than PreveCeutical Medical, Inc., analysts believe Venus Concept, Inc. is more attractive than PreveCeutical Medical, Inc..

PreveCeutical Medical, Inc. has a beta of 0.617, which suggesting that the stock is 38.252% less volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.111, suggesting its less volatile than the S&P 500 by 111.094%.

PreveCeutical Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PreveCeutical Medical, Inc. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.

PreveCeutical Medical, Inc. quarterly revenues are --, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. PreveCeutical Medical, Inc.'s net income of -$623K is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, PreveCeutical Medical, Inc.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PreveCeutical Medical, Inc. is -- versus 0.04x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.